| Literature DB >> 35832446 |
Liqiang Qian1, Yinjie Zhou2, Wanqin Zeng3, Xiaoke Chen1, Zhengping Ding1, Yujia Shen3, Yifeng Qian4, Davide Tosi5, Mario Silva6, Yuchen Han7, Xiaolong Fu3.
Abstract
Background: Intraoperative frozen section (FS) analysis has been used to guide the extent of resection in patients with solitary pulmonary nodules (SPNs), but its accuracy varies greatly among different hospitals. Artificial intelligence (AI) and multidimensional data technology are developing rapidly these years, meanwhile, surgeons need better methods to guide the surgical strategy of SPNs. We established predicting models combining FS results with multidimensional perioperative clinical features using logistic regression analysis and the random forest (RF) algorithm to get more accurate extent of SPN resection.Entities:
Keywords: Solitary pulmonary nodule (SPN); diagnostic accuracy; frozen section (FS); random forest (RF); surgical resection
Year: 2022 PMID: 35832446 PMCID: PMC9271446 DOI: 10.21037/tlcr-22-395
Source DB: PubMed Journal: Transl Lung Cancer Res ISSN: 2218-6751
Figure 1Flowchart of patient inclusion. CT, computed tomography; FS, frozen section.
Clinicopathologic characteristics of patients included in the study (N=3,098)
| Characteristics | Total (N=3,098) | AAH (n=16) | AIS (n=432) | MIA (n=634) | IAC (n=1,385) | Other infiltrative malignancies (n=62) | Low-grade malignancies (n=5) | Benign (n=564) | P |
|---|---|---|---|---|---|---|---|---|---|
| Age (mean ± SD) (years) | 54.57±10.96 | 55.3±9.84 | 49.3±11.4 | 50.7±11.7 | 58.1±9.14 | 63.4±7.0 | 63.2±4.9 | 53.2±10.7 | <0.001 |
| Sex, n (%) | <0.001 | ||||||||
| Male | 1,237 (39.9) | 3 (18.8) | 138 (31.9) | 176 (27.8) | 576 (41.6) | 53 (85.5) | 2 (40.0) | 289 (51.2) | |
| Female | 1,861 (60.1) | 13 (81.2) | 294 (68.1) | 458 (72.2) | 809 (58.4) | 9 (14.5) | 3 (60.0) | 275 (48.8) | |
| Surgical methods, n (%) | <0.001 | ||||||||
| Wedge resection | 1,104 (35.6) | 11 (68.8) | 267 (61.8) | 284 (44.8) | 62 (4.5) | 1 (1.6) | 2 (40.0) | 477 (84.6) | |
| Segmentectomy | 536 (17.3) | 3 (18.8) | 133 (30.8) | 215 (33.9) | 95 (6.9) | 2 (3.2) | 2 (40.0) | 86 (15.2) | |
| Lobectomy | 1,458 (47.1) | 2 (12.6) | 32 (7.4) | 135 (21.3) | 1,228 (88.6) | 59 (95.2) | 1 (20.0) | 1 (0.2) | |
| Location of tumor, n (%) | 0.002 | ||||||||
| RUL | 1,106 (35.7) | 9 (56.3) | 174 (40.3) | 236 (37.2) | 513 (37.0) | 18 (29.0) | 1 (20.0) | 155 (27.5) | |
| RML | 84 (2.7) | 1 (6.3) | 9 (2.1) | 21 (3.3) | 18 (1.3) | 0 | 0 | 35 (6.2) | |
| RLL | 541 (17.5) | 0 | 50 (11.6) | 106 (16.7) | 238 (17.2) | 7 (11.3) | 2 (40.0) | 138 (24.5) | |
| LUL | 860 (25.8) | 5 (31.2) | 141 (32.6) | 178 (28.1) | 391 (28.3) | 23 (37.1) | 0 | 122 (21.6) | |
| LLL | 507 (16.3) | 1 (6.2) | 58 (13.4) | 93 (14.7) | 225 (16.2) | 14 (22.6) | 2 (40.0) | 114 (20.2) | |
| Maximum diameter of tumor, n (%) | <0.001 | ||||||||
| ≤1 cm | 1,341 (43.3) | 13 (81.3) | 407 (94.2) | 478 (75.4) | 151 (10.9) | 3 (4.9) | 3 (60.0) | 286 (50.7) | |
| 1< d ≤2 cm | 1,226 (39.6) | 2 (12.5) | 23 (5.3) | 151 (23.8) | 801 (57.8) | 26 (41.9) | 1 (20.0) | 222 (39.4) | |
| 2< d ≤3 cm | 531 (17.1) | 1 (6.2) | 2 (0.5) | 5 (0.8) | 433 (31.3) | 33 (53.2) | 1 (20.0) | 56 (9.9) | |
| Lymph node situation, n (%) | 0.957 | ||||||||
| N0 | 3,007 (97.1) | 16 (100.0) | 432 (100.0) | 634 (100.0) | 1,301 (93.9) | 55 (88.7) | 5 (100.0) | 564 (100.0) | |
| N1 | 31 (1.0) | 0 | 0 | 0 | 29 (2.1) | 2 (3.2) | 0 | 0 | |
| N2 | 60 (1.9) | 0 | 0 | 0 | 55 (4.0) | 5 (8.1) | 0 | 0 | |
| CT imaging, n (%) | |||||||||
| GGO component | <0.001 | ||||||||
| With | 2,378 (76.8) | 16 (100.0) | 432 (100.0) | 634 (100.0) | 1,017 (73.4) | 1 (1.6) | 1 (20.0) | 277 (49.1) | |
| Without | 720 (23.2) | 0 | 0 | 0 | 368 (26.6) | 61 (98.4) | 4 (80.0) | 287 (50.9) | |
| Pleural indentation | <0.001 | ||||||||
| Yes | 1,135 (36.6) | 0 | 88 (20.4) | 182 (28.7) | 826 (59.6) | 38 (61.3) | 0 | 1 (0.2) | |
| No | 1,963 (63.4) | 16 (100.0) | 344 (79.6) | 452 (71.3) | 559 (40.4) | 24 (38.7) | 5 (100.0) | 563 (99.8) | |
| Smoking history, n (%) | 0.001 | ||||||||
| Yes | 239 (7.7) | 2 (12.5) | 12 (2.8) | 26 (4.1) | 119 (8.6) | 44 (71.0) | 0 | 36 (6.4) | |
| No | 2,859 (92.3) | 14 (87.5) | 420 (97.2) | 608 (95.9) | 1,266 (91.4) | 18 (29.0) | 5 (100.0) | 528 (93.6) | |
| Tumor biomarkers (mean ± SD) | |||||||||
| CEA | 2.76±7.9 | 2±1.18 | 1.77±1.51 | 1.88±1.26 | 3.66±11.5 | 4.37±6.12 | 2.29±1.27 | 2.66±1.74 | 0.438 |
| CA19-9 | 2.48±1.17 | 2.24±1.24 | 2.28±0.98 | 2.38±1.09 | 2.54±1.11 | 3.11±1.27 | 2.83±0.87 | 2.57±1.44 | <0.001 |
| CYFRA21-1 | 0.85±0.85 | 0.98±0.80 | 0.812±0.50 | 0.847±0.82 | 0.861±0.98 | 1.06±0.71 | 0.68±0.11 | 0.843±0.79 | 0.711 |
| NSE | 18.14±6.68 | 16.5±6.27 | 17.9±6.62 | 17.7±6.44 | 18.5±7.05 | 17.00±4.61 | 17±3.62 | 18±6.28 | 0.685 |
| CA125 | 12.06±15.4 | 11±5.53 | 13.6±35.2 | 12.1±10.3 | 11.5±7.83 | 11±4.54 | 10.5±3.64 | 12.3±9.05 | 0.433 |
Minimum 1 cm adenocarcinoma with lymph node metastasis (N1, N2), 1.5 cm squamous carcinoma with lymph node metastasis (N1). AAH, atypical adenomatous hyperplasia; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; IAC, invasive adenocarcinoma; SD, standard deviation; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe; CT, computed tomography; GGO, ground glass opacity; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; CYFRA21-1, cytokeratin 19 fragment antigen21-1; NSE, neuron-specific enolase; CA125, cancer antigen 125.
Comparison of frozen section and final pathology results
| Frozen section results | Final pathology results, n (%) | ||||||
|---|---|---|---|---|---|---|---|
| AAH (n=16) | AIS (n=432) | MIA (n=634) | IAC (n=1,385) | Other types of malignancy (n=62) | Low-grade malignancy (n=5) | Benign (n=564) | |
| AAH | 13 (81.3*) | 13 (3.0) | 3 (0.5) | 4 (0.3) | 0 | 0 | 0 |
| AIS | 0 | 148 (34.3*) | 23 (3.6) | 2 (0.1) | 0 | 0 | 0 |
| MIA | 0 | 77 (17.8) | 56 (8.8*) | 9 (0.6) | 0 | 0 | 0 |
| IAC | 1 (6.2) | 12 (2.8) | 10 (1.6) | 1,068 (77.2*) | 1 (1.6) | 0 | 0 |
| Other types of malignancy | 0 | 0 | 0 | 0 | 55 (88.7*) | 1 (20.0) | 0 |
| Low-grade malignancy | 0 | 0 | 0 | 0 | 0 | 2 (40.0*) | 1 (0.2) |
| Benign | 0 | 4 (0.9) | 1 (0.2) | 2 (0.1) | 2 (3.2) | 1 (20.0) | 555 (98.4*) |
| Equivocal | 2 (12.5) | 178 (41.2) | 541 (85.3) | 300 (21.7) | 4 (6.5) | 1 (20.0) | 8 (1.4) |
*, indicates the frozen section accuracy for each type of solitary pulmonary nodule. AAH, atypical adenomatous hyperplasia; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; IAC, invasive adenocarcinoma.
Univariable and multivariable analyses of factors contributing to incorrect frozen section diagnosis
| Variable | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | ||
| Age | 0.97 (0.97, 0.98) | <0.001 | 1.01 (1.00, 1.02) | 0.246 | |
| Maximum diameter | 0.29 (0.25, 0.33) | <0.001 | 0.38 (0.30, 0.47) | <0.001 | |
| Sex | |||||
| Male | Reference | Reference | |||
| Female | 1.80 (1.54, 2.11) | <0.001 | 1.13 (0.91, 1.40) | 0.272 | |
| Location | |||||
| LUL | Reference | Reference | |||
| LLL | 0.97 (0.77, 1.23) | 0.819 | 1.30 (0.95, 1.76) | 0.096 | |
| RUL | 1.15 (0.95, 1.38) | 0.147 | 1.20 (0.94, 1.52) | 0.138 | |
| RML | 0.95 (0.58, 1.51) | 0.825 | 1.14 (0.55, 2.35) | 0.725 | |
| RLL | 0.81 (0.64, 1.02) | 0.075 | 0.95 (0.70, 1.30) | 0.769 | |
| Pathology | |||||
| AAH | Reference | Reference | |||
| AIS | 3.40 (1.08, 14.99) | 0.059 | 3.99 (1.24, 17.80) | 0.035 | |
| MIA | 28.77 (9.05, 127.41) | <0.001 | 43.50 (13.36, 195.34) | <0.001 | |
| IAC | 1.29 (0.41, 5.64) | 0.696 | 5.15 (1.58, 23.14) | 0.013 | |
| Other types of cancer | 0.46 (0.11, 2.42) | 0.320 | 8.30 (1.72, 47.26) | 0.010 | |
| Low-grade malignancy | 1.08 (0.05, 11.69) | 0.950 | 3.55 (0.13, 49.48) | 0.367 | |
| Benign | 0.06 (0.02, 0.31) | <0.001 | 0.16 (0.04, 0.79) | 0.013 | |
| Pleural indentation | |||||
| No | Reference | Reference | |||
| Yes | 0.77 (0.66, 0.90) | 0.001 | 0.86 (0.69, 1.06) | 0.154 | |
| GGO component | |||||
| No | Reference | Reference | |||
| Yes | 16.26 (11.55, 23.72) | <0.001 | 4.27 (2.85, 6.62) | <0.001 | |
| History of smoking | |||||
| No | Reference | Reference | |||
| Yes | 0.51 (0.37, 0.70) | <0.001 | 0.95 (0.61, 1.46) | 0.807 | |
OR, odds ratio; CI, confidence interval; LUL, left upper lobe; LLL, left lower lobe; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; AAH, atypical adenomatous hyperplasia; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; IAC, invasive adenocarcinoma; GGO, ground glass opacity.
Figure 2ROC curve, NRI, and calibration plot of the three models in the internal validation cohort. (A) AUC for the three models; (B) NRI of the three models; (C) calibration plots of Model 1; (D) calibration plots of Model 2; (E) calibration plots of Model 3. AUC, area under the ROC curve; NRI, net reclassification index; Pr, probability; ROC, receiver operating characteristic.
Figure 3ROC curve, NRI, and calibration plot of the three models in the external validation cohort. (A) AUC for the three models; (B) NRI of the three models; (C) calibration plots of Model 1; (D) calibration plots of Model 2; (E) calibration plots of Model 3. AUC, area under the ROC curve; NRI, net reclassification index; Pr, probability; ROC, receiver operating characteristic.
Diagnostic accuracy of the different models
| Cohorts | Model | Accuracy (%) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|---|---|
| Internal validation | Model 1 | 62.82 | 76.82 | 49.70 | 58.88 | 69.58 |
| Model 2 | 79.65 | 78.97 | 80.28 | 78.97 | 80.28 | |
| Model 3 | 82.76 | 84.98 | 80.68 | 80.49 | 85.14 | |
| External validation | Model 1 | 62.39 | 73.47 | 54.41 | 53.73 | 74.00 |
| Model 2 | 82.05 | 77.55 | 85.29 | 79.17 | 84.06 | |
| Model 3 | 87.18 | 85.71 | 88.24 | 84.00 | 89.55 |
NPV, negative predictive value; PPV, positive predictive value.